Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials

This post hoc analysis of MONARCH 2 and MONARCH 3 assesses the efficacy, safety, and pharmacokinetics (PK) of abemaciclib in combination with endocrine therapy (ET) in East Asian patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2‐negative (HER2−) advanced breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Toi, Masakazu, Inoue, Kenichi, Masuda, Norikazu, Iwata, Hiroji, Sohn, Joohyuk, Hae Park, In, Im, Seock‐Ah, Chen, Shin‐Cheh, Enatsu, Sotaro, Turner, P. Kellie, André, Valérie A. M., Hardebeck, Molly C., Sakaguchi, Sachi, Goetz, Matthew P., Sledge, George W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177785/
https://www.ncbi.nlm.nih.gov/pubmed/33686753
http://dx.doi.org/10.1111/cas.14877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177785/
https://www.ncbi.nlm.nih.gov/pubmed/33686753
http://dx.doi.org/10.1111/cas.14877

Ejemplares similares